Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield, Ulrich Beuers, Christophe Corpechot, et al.
Journal of Hepatology (2017) Vol. 67, Iss. 1, pp. 145-172
Open Access | Times Cited: 1146

Showing 1-25 of 1146 citing articles:

Burden of liver diseases in the world
Sumeet K. Asrani, Harshad Devarbhavi, John E. Eaton, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 1, pp. 151-171
Closed Access | Times Cited: 3043
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1148
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Christophe Corpechot, Olivier Chazouillères, Alexandra Rousseau, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 23, pp. 2171-2181
Open Access | Times Cited: 482
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
Hitoshi Yoshiji, Sumiko Nagoshi, Takemi Akahane, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 7, pp. 593-619
Open Access | Times Cited: 293
Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective
Jan Damoiseaux, Luís Eduardo Coelho Andrade, Orlando Gabriel Carballo, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 7, pp. 879-889
Open Access | Times Cited: 292
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Gideon M. Hirschfield, Jessica Dyson, Graeme Alexander, et al.
Gut (2018) Vol. 67, Iss. 9, pp. 1568-1594
Open Access | Times Cited: 282
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini, Mailis Maes, Gwilym J. Webb, et al.
Nature (2022) Vol. 615, Iss. 7950, pp. 134-142
Open Access | Times Cited: 230
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
Maren H. Harms, Henk R. van Buuren, Christophe Corpechot, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 2, pp. 357-365
Open Access | Times Cited: 205
EASL Clinical Practice Guidelines on sclerosing cholangitis
Olivier Chazouillères, Ulrich Beuers, Annika Bergquist, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 761-806
Closed Access | Times Cited: 194
Secondary Osteoporosis
Peter R. Ebeling, Hanh H. Nguyen, Jasna Aleksova, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 2, pp. 240-313
Open Access | Times Cited: 190
Primary biliary cholangitis
Ana Lleò, Giu-Qiang Wang, M. Eric Gershwin, et al.
The Lancet (2020) Vol. 396, Iss. 10266, pp. 1915-1926
Closed Access | Times Cited: 178
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
Joong‐Won Park, Yoon Jun Kim, Do Young Kim, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 4, pp. 684-691
Open Access | Times Cited: 172
A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models
Enrico Longato, Martina Vettoretti, Barbara Di Camillo
Journal of Biomedical Informatics (2020) Vol. 108, pp. 103496-103496
Open Access | Times Cited: 153
Evidence‐based clinical practice guidelines for liver cirrhosis 2020
Hitoshi Yoshiji, Sumiko Nagoshi, Takemi Akahane, et al.
Hepatology Research (2021) Vol. 51, Iss. 7, pp. 725-749
Open Access | Times Cited: 133
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 133
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
Jörn M. Schattenberg, Albert Parés, Kris V. Kowdley, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1344-1354
Closed Access | Times Cited: 125
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
Ferenc E. Mózes, Jenny Lee, Yasaman Vali, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 704-713
Open Access | Times Cited: 113
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, et al.
New England Journal of Medicine (2023) Vol. 390, Iss. 9, pp. 795-805
Closed Access | Times Cited: 108
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis
Hong You, Xiong Ma, Cumali Efe, et al.
Hepatology International (2022) Vol. 16, Iss. 1, pp. 1-23
Open Access | Times Cited: 82
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Gideon M. Hirschfield, Christopher L. Bowlus, Marlyn J. Mayo, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 9, pp. 783-794
Closed Access | Times Cited: 74
Mitochondrial cholesterol: Metabolism and impact on redox biology and disease
Leire Goicoechea, Laura Conde de la Rosa, Sandra Torres, et al.
Redox Biology (2023) Vol. 61, pp. 102643-102643
Open Access | Times Cited: 71
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, et al.
Hepatology (2023) Vol. 78, Iss. 2, pp. 397-415
Open Access | Times Cited: 64
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Juan Trivella, Binu V. John, Cynthia Levy
Hepatology Communications (2023) Vol. 7, Iss. 6
Open Access | Times Cited: 63
Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy
Bo Tang, Li Tang, Shengpeng Li, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 55
New Treatment Paradigms in Primary Biliary Cholangitis
Cynthia Levy, Michael P. Manns, Gideon M. Hirschfield
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2076-2087
Closed Access | Times Cited: 52
Page 1 - Next Page

Scroll to top